Thus, while targeting the tumor-promoting aspects of TGFβ is appealing in colon cancer given its pro-metastatic function in advanced disease, our data suggests that administering systemic TGFBR-inhibitors may further accelerate carcinogenesis in many, if not all, colon cancer patients. The gene discussed is TGFB1; the disease is malignant colon neoplasm.